Theratechnologies Inc (THTX)

OS Therapies. (NYSE American: $OSTX) announced positive biomarker data from its Phase 2b clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/os-therapies-1. The results showed that specific immune markers in patients’ blood could distinguish long-term survivors (≥2 years) from short-term survivors (<1 year). According to the company, this adds resolution to the clinical data and increases the interpretability of the 2-year overall survival results for regulatory agencies. The pathway analysis was pre-specified and based on data from a 118-patient canine osteosarcoma study published in February 2025. When the same pre-specified pathway was confirmed in humans, it validated what the company calls Comparative Oncology: using dog cancer research to inform human drug development. Regulatory approval targets remain: UK by end of Q2 2026, US by end of Q3 2026, and Europe by year-end 2026. If the company receives Accelerated Approval prior to September 30, 2026, it would become eligible to receive a Priority Review Voucher under the Rare Pediatric Disease Designation program. The most recent PRV sale, in January 2026, was valued at $200 million. Paul Romness, MHP, Chairman & CEO noted: “Leveraging the power of Comparative Oncology, we were able to train and test potentially predictive biomarkers from the Canine Metastatic Osteosarcoma Trial in order to form a hypothesis to test in a pre-specified way in the Human Metastatic Osteosarcoma Trial. We believe the confirmation of this pre-specified pathway analysis in humans adds significant resolution to our clinical data, increasing the clinical interpretability of the 2-year overall survival data for regulatory agencies. The confirmation of a pre-specified canine biomarker pathway being upregulated in a comparable human clinical study population leveraged canine biomarker data to a generate hypothesis that was tested in a pre-specified way and confirmed as a surrogate marker of clinical efficacy. This biomarker data strengthens our pending Biologics License Application (BLA) submission.” See the announcement at: https://ir.ostherapies.com/news-events/press-releases/detail/97/os-therapies-announces-positive-biomarker-data-from-phase Led by CEO Paul Romness and an executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), Jack Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on advancing immunotherapies for osteosarcoma and other solid tumors. Learn more at https://www.ostherapies.com and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted OSTX stock. B2i Digital, Inc. is not a broker-dealer or investment adviser. This post is for informational purposes only and is not an offer to sell or a solicitation to buy any security. Investors should conduct their own research and consult with a qualified financial adviser before making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $THTX, $CGTX, $XBI

$OSTX $THTX $CGTX $XBI $20.00 will rerate overnight when bla is filed. That prv is worth 160 million according to company filing. Loading the boat down here in full accumulation mode

OS Therapies (NYSE American: $OSTX) announced that its wholly owned subsidiary, OS Animal Health (OSAH), has filed a Form S-1 with the U.S. Securities and Exchange Commission in preparation for a proposed initial public offering. OSAH intends to list on either the NYSE American or Nasdaq Capital Markets in the first half of 2026. OS Therapies is a B2i Digital Featured Company. View the full company profile at https://b2idigital.com/os-therapies-1. Under the proposed structure, OS Therapies shareholders are expected to receive one share of OS Animal Health for every ten shares of OSTX owned as of a record date to be determined in the first half of 2026. OS Animal Health will operate as a standalone animal health company focused on the re-establishment of USDA conditional approval and commercialization of OST-HER2 for canine osteosarcoma and other HER2-positive cancers in animals. From a scientific standpoint, the company highlighted growing evidence supporting the relevance of naturally occurring canine osteosarcoma as a translational model for human disease. Multiple OST-HER2 canine studies have demonstrated immune biomarker activation associated with improved clinical outcomes, with additional peer-review research currently under submission. In parallel with the planned OS Animal Health IPO, OS Therapies reiterated that biomarker data from its Phase 2b OST-HER2 trial in human pulmonary metastatic osteosarcoma will be released on January 15, 2026. These data are expected to support the company’s upcoming Biologics Licensing Application submission to the U.S. FDA under the Accelerated Approval pathway. Commenting on the announcement, Paul Romness, Chairman & CEO of OS Therapies and Interim-CEO of OS Animal Health, stated: “As parent company OS Therapies diligently pursues a Biologics Licensing Application (BLA) under the Accelerated Approval Program (Accelerated Approval) for OST-HER2 in human osteosarcoma, we have been relying heavily on data generated from naturally occurring osteosarcoma in domestic canines to generate key immune biomarker signature hypotheses that we are using to pre-specify treatment outcomes biomarkers in our human OST-HER2 metastatic osteosarcoma program. Two (2) separate research studies in different disease settings of canine osteosarcoma have shown improved patient outcomes in response to OST-HER2 treatment, with specific immune biomarkers being associated with antitumor immunity and improved clinical outcomes. There is a significant market opportunity for a novel treatment such as OST-HER2 that has demonstrated strong immune activation and treatment outcomes in canine osteosarcoma.” Read the full announcement: https://ir.ostherapies.com/news-events/press-releases/detail/96/os-therapies-announces-filing-form-s-1-of-os-animal-health-subsidiary Led by CEO Paul Romness and an executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), Jack Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on advancing immunotherapies for osteosarcoma and other solid tumors. Learn more at https://www.ostherapies.com and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted OSTX stock. B2i Digital, Inc. is not a broker-dealer or investment adviser. This post is for informational purposes only and is not an offer to sell or a solicitation to buy any security. Investors should conduct their own research and consult with a qualified financial adviser before making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $THTX, $CGTX, $XBI

$THTX took an almost $40K loss here and wasted almost 4 years holding this turd. I’ve since recouped those losses x4 at CRML and UURAF. This company is run by morons and all they have is a cancer drug that doesn’t work and aids. FU Thera 🖕🏻

$THTX guys what happened after acquisition. Did you get money

$THTX need u !

$THTX Great piece that accurately captures THTX's current position. So if you want to refresh your understanding of THTX or learn about THTX for the first time, this is essential reading. https://beyondspx.com/quote/THTX/analysis/theratechnologies-a-strategic-acquisition-validates-niche-innovation-and-commercial-strength-nasdaq-thtx

$THTX NASDAQ Equity Corporate Actions Alert # 2025 - 517 Information Regarding the Plan of Arrangement of Theratechnologies Inc. (THTX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-517 At a special meeting held on September 12, 2025, the shareholders of Theratechnologies Inc. (THTX) approved a Plan of Arrangement involving CB Biotechnology, LLC, an affiliate of Future Pak, LLC. The arrangement is tentatively scheduled to close on September 25, 2025. Merger consideration: THTX shareholders will receive $3.01 and one (1) contingent value right (CVR) for each share held.

$THTX is there anything good with this stock or we sell it

$THTX Now we just sit back and wait for the CVR's to meet milestones over the next 3 years.